Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Silence Therapeutics (SLNCF) Cost of Revenue (2020 - 2025)

Historic Cost of Revenue for Silence Therapeutics (SLNCF) over the last 6 years, with Q3 2025 value amounting to $64000.0.

  • Silence Therapeutics' Cost of Revenue fell 9824.13% to $64000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 8041.53%. This contributed to the annual value of $11.8 million for FY2024, which is 821.48% down from last year.
  • Latest data reveals that Silence Therapeutics reported Cost of Revenue of $64000.0 as of Q3 2025, which was down 9824.13% from $85000.0 recorded in Q2 2025.
  • Over the past 5 years, Silence Therapeutics' Cost of Revenue peaked at $5.5 million during Q1 2023, and registered a low of $2119.4 during Q1 2021.
  • Moreover, its 5-year median value for Cost of Revenue was $2.8 million (2024), whereas its average is $2.4 million.
  • In the last 5 years, Silence Therapeutics' Cost of Revenue surged by 14393483.68% in 2022 and then tumbled by 9824.13% in 2025.
  • Over the past 5 years, Silence Therapeutics' Cost of Revenue (Quarter) stood at $2.8 million in 2021, then soared by 64.44% to $4.5 million in 2022, then plummeted by 63.09% to $1.7 million in 2023, then rose by 21.99% to $2.0 million in 2024, then crashed by 96.86% to $64000.0 in 2025.
  • Its last three reported values are $64000.0 in Q3 2025, $85000.0 for Q2 2025, and $54000.0 during Q1 2025.